Medical Science Liaisons: Optimizing their impact during product launch

Register now

May 03, 2016

Register Save to Calendar



Knowing the key decision makers and KOLs is an important element of any market access strategy. To correctly communicate complex scientific trial data to these stakeholders before launching a new drug requires the right knowledge and capabilities. As therapeutic specialists with advanced scientific training, Medical Science Liaisons (MSL) working in the field possess the deep expertise and experience needed to conduct peer-to-peer discussions with payers and KOLs, and can help to facilitate market entry and product uptake. 

Join our upcoming webinar and get a greater understanding of the impact MSLs can have as we explore a recent case study of a small U.S. biotech company. Listen as they share how they overcame the challenges and successfully deployed MSLs across Europe.


Prof. Peter Rutherford, MD, PhD
Vice President Integrated Market Access, EMEA and Emerging Markets

Peter Rutherford is responsible for strategy and execution of Integrated Market Access and patient centric services within Europe and Emerging Markets for Quintiles. Peter’s background includes twenty-plus years of scientific experience gained from working across academia, industry, payers and providers. He is a highly experienced leader in the area of medical affairs and an established thought leader in relation to managing KOL relationships with regards to patient support programs. His broad geographic experience in leading medical affairs and Phase IV scientific communication has provided a deep understanding of the different stakeholder requirements, and the ability to collaborate effectively across the organization.

Todd J. Yancey, MD
Senior Vice President, Global Medical Affairs
Clovis Oncology

Todd J. Yancey, MD joined Clovis in July, 2014 as Senior Vice President – Global Medical Affairs. He brings over 30 years of clinical, medical and scientific experience. Having completed undergraduate and medical school training at the University of Virginia, he pursued internship, residency and fellowship training at The New York Presbyterian Hospital/Weill Cornell Medical College. While there over 14 years, he served as teaching faculty for the Medical College and clinical faculty for Hospital with a focus upon HIV disease clinical research and management. He has been in biotechnology since 2000 with increasing levels of seniority at Amgen (Aranesp, Neulasta, Enbrel), Genentech (Tarceva), Onyx (Nexavar, Kyprolis) and Medivation (Xtandi) prior to joining Clovis. Serving in executive management since 2006, he has spent his time working internationally in both global medical affairs and clinical development with areas of responsibility including: Medical Science Liaisons, Medical Development, Scientific Communications, Health Outcomes, Safety/Pharmacovigilance, Program Leadership, Alliance Management, Life Cycle Management, Clinical Development, Biometrics and Clinical Operations.